EPCCS 2019 Read impressions of the updates on stroke prevention in AF, hypertension, HF and CV risk in diabetes, with emphasis on challenges faced in patients with multimorbidities.
EPCCS 2019 Slides prepared and presented by prof. Richard Hobbs (Oxford, United Kingdom), here offered as an educational service.
EPCCS 2019 Slides prepared and presented by prof. Kamlesh Khunti (Leicester, UK) here offered as an educational service.
EPCCS 2019 Prof. Hobbs set the scene for the presentation of prof. Khunti, by showing how diabetes is linked to CVD risk, after which prof. Khunti outlined how this risk can best be reduced with therapy.
ACC 2019 The new guideline promotes a healthy lifestyle throughout life, and encourages physicians to assess social determinants of health to optimally implement the recommendations.
A study with representative US citizens showed similar trends for most CV risk factors between men and women from 2001 to 2016, with the exception of BMI and total cholesterol, and sex differences for control of hypertension, diabetes and dyslipidemia.
Download the EPCCS Practical Guidance Document, which provides a brief scientific background on the need for and practical guidance on management of hyperglycaemia and the increased CV risk in patients with type 2 diabetes. The document focusses on challenges faced in clinical reality.
This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.
Learn more about the activities of EPCCS that are aimed at supporting primary care professionals manage their patients with cardiovascular and cardiometabolic disease.
High number of ideal CV health metrics is associated with low incidence of diabetes in subjects with normal fasting glucose, but not in those with impaired fasting glucose.
Use of aspirin resulted in reduction of composite of CV mortality, nonfatal MI and nonfatal stroke in primary prevention setting, shown in a meta-analysis including 13 trials with more than 164.000 individuals, but at the cost of higher risk of major bleeding.
The Diabetes Lifetime-perspective prediction (DIAL) model was developed and can be used in the U-Prevent decision tool to predict individual CVD-free life expectancy and the effect of lifelong treatment on CVD-free life-years gained.